Miltefosine

Miltefosine structure

Miltefosine is a pharmaceutical agent primarily prescribed for the treatment of leishmaniasis and specific free-living amoeba infections. Marketed under the brand name Impavido among other labels, this drug has revolutionized the treatment of some challenging parasitic diseases, particularly within the tropical disease domain.

Indications

Miltefosine has shown therapeutic benefits against a spectrum of parasitic infections:

Leishmaniasis: The drug combats all three clinical manifestations of this condition:

- Cutaneous leishmaniasis^[1]
- Visceral leishmaniasis^[2]
- Mucosal leishmaniasis

Free-Living Amoeba Infections:

- Naegleria fowleri: A rare, but often fatal, brain infection^[3].
- Balamuthia mandrillaris: An amoeba that affects the skin and the central nervous system.

In certain scenarios or for particular patient demographics, Miltefosine might be prescribed alongside other antiparasitic treatments, such as liposomal amphotericin B or paromomycin.

Administration

Administered orally, Miltefosine offers a preferable alternative to the often cumbersome intravenous or intramuscular treatments generally prescribed for parasitic afflictions.

Mechanism of Action

While ongoing research is still demystifying its exact mechanism, existing evidence suggests that Miltefosine disrupts the cellular metabolism of parasites, halting their growth and proliferation^[4].

Adverse Effects

Like many drugs, Miltefosine has associated side effects that can range from mild to severe:

Common:

- Vomiting
- Abdominal pain
- Fever
- Headaches
- Impaired kidney function

Severe:

- Stevens-Johnson syndrome: A severe dermatological reaction.
- Thrombocytopenia: A condition characterized by reduced blood platelet count^[5].

Contraindications

Pregnant individuals should refrain from Miltefosine due to documented teratogenic effects on the fetus^[6]. Lactating mothers should also avoid this medication due to the potential risk it poses to infants.

Conclusion

Miltefosine heralds a new era in the treatment of leishmaniasis and certain amoebic infections. As the medical landscape continues its evolution, the balance between this drug's therapeutic potential and its associated risks becomes ever more critical, ensuring both patient safety and effective outcomes.

References

↑ Sundar, S., & Chakravarty, J. (2015). Leishmaniasis: An update of current pharmacotherapy. Expert Opinion on Pharmacotherapy, 16(2), 237-252.
↑ Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., ... & Boelaert, M. (2007). Visceral leishmaniasis: What are the needs for diagnosis, treatment, and control? Nature Reviews Microbiology, 5(11), S7-S16.
↑ Grace, E., Asbill, S., & Virga, K. (2015). Naegleria fowleri: Pathogenesis, diagnosis, and treatment options. Antimicrobial Agents and Chemotherapy, 59(11), 6677-6681.
↑ Dorlo, T. P., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012). Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy, 67(11), 2576-2597.
↑ Rijal, S., Ostyn, B., Uranw, S., Rai, K., Bhattarai, N. R., Dorlo, T. P., ... & Boelaert, M. (2013). Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinical Infectious Diseases, 56(11), 1530-1538.
↑ Dorlo, T. P., Huitema, A. D., Beijnen, J. H., & de Vries, P. J. (2012). Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 56(7), 3864-3872.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Transform your life with W8MD's budget GLP-1 injections from $125.

W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:

- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC

Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

[1] Sundar, S., & Chakravarty, J. (2015). Leishmaniasis: An update of current pharmacotherapy. Expert Opinion on Pharmacotherapy, 16(2), 237-252.

[2] Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., ... & Boelaert, M. (2007). Visceral leishmaniasis: What are the needs for diagnosis, treatment, and control? Nature Reviews Microbiology, 5(11), S7-S16.

[3] Grace, E., Asbill, S., & Virga, K. (2015). Naegleria fowleri: Pathogenesis, diagnosis, and treatment options. Antimicrobial Agents and Chemotherapy, 59(11), 6677-6681.

[4] Dorlo, T. P., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012). Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy, 67(11), 2576-2597.

[5] Rijal, S., Ostyn, B., Uranw, S., Rai, K., Bhattarai, N. R., Dorlo, T. P., ... & Boelaert, M. (2013). Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinical Infectious Diseases, 56(11), 1530-1538.

[6] Dorlo, T. P., Huitema, A. D., Beijnen, J. H., & de Vries, P. J. (2012). Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 56(7), 3864-3872.

[1]

[2]

[3]

[4]

[5]

[6]